Detail akcie Vertex Pharma online

Business Summary: Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The Company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. It also has a clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. The Company's pipeline also includes PALSONIFY (paltusotine) and atumelnant. PALSONIFY is the once-daily oral therapy for acromegaly.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Vertex Pharmaceuticals Inc revenues increased 10% to $6.32B. Net income increased 27% to $2.13B. Revenues reflect ALYFTREK segment increase from $210.7M to $998M, CASGEVY segment increase from $44.6M to $119.3M, United States segment increase of 10% to $3.83B, Europe segment increase of 11% to $1.93B. Net income benefited from Intangible asset impairment charge decrease from $379M (expense) to $0K.